DK2576638T3 - Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf - Google Patents
Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf Download PDFInfo
- Publication number
- DK2576638T3 DK2576638T3 DK11787302.6T DK11787302T DK2576638T3 DK 2576638 T3 DK2576638 T3 DK 2576638T3 DK 11787302 T DK11787302 T DK 11787302T DK 2576638 T3 DK2576638 T3 DK 2576638T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic procedures
- polymer conjugated
- metap2 inhibitors
- conjugated metap2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/10—Acylation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2800/00—Copolymer characterised by the proportions of the comonomers expressed
- C08F2800/10—Copolymer characterised by the proportions of the comonomers expressed as molar percentages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2800/00—Copolymer characterised by the proportions of the comonomers expressed
- C08F2800/20—Copolymer characterised by the proportions of the comonomers expressed as weight or mass percentages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34792410P | 2010-05-25 | 2010-05-25 | |
PCT/US2011/037857 WO2011150022A2 (en) | 2010-05-25 | 2011-05-25 | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2576638T3 true DK2576638T3 (da) | 2021-03-15 |
Family
ID=45004745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11787302.6T DK2576638T3 (da) | 2010-05-25 | 2011-05-25 | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
Country Status (7)
Country | Link |
---|---|
US (7) | US9320805B2 (da) |
EP (2) | EP2576638B1 (da) |
CN (3) | CN103140512B (da) |
CA (1) | CA2828605C (da) |
DK (1) | DK2576638T3 (da) |
ES (1) | ES2853204T3 (da) |
WO (1) | WO2011150022A2 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
US9320805B2 (en) | 2010-05-25 | 2016-04-26 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
CN104364251B (zh) * | 2012-05-09 | 2017-02-22 | 扎夫根股份有限公司 | 烟曲霉醇型化合物及其制备和使用方法 |
CA2908993C (en) | 2013-04-10 | 2023-05-23 | Syndevrx, Inc. | Metap2 inhibitors and methods of treating obesity |
WO2015029615A1 (ja) * | 2013-08-26 | 2015-03-05 | 独立行政法人科学技術振興機構 | 接着剤 |
US11506663B2 (en) * | 2014-05-13 | 2022-11-22 | Vastcon | Methionine aminopeptidase overexpression in the peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer screening, diagnosis and prognosis |
DK3386956T3 (da) | 2015-12-10 | 2021-10-11 | Syndevrx Inc | Fumagillolderivater og polymorfer deraf |
EP3402529A1 (en) * | 2016-01-11 | 2018-11-21 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
WO2020087077A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx,Inc. | Biomarkers of metap2 inhibitors and applications thereof |
WO2024036274A1 (en) * | 2022-08-10 | 2024-02-15 | Syndevrx, Inc. | Metap2 inhibitors for the treatment of pulmonary fibrosis |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2803586A (en) | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
AU9376998A (en) | 1997-09-02 | 1999-03-22 | Johns Hopkins University School Of Medicine, The | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
AU3352799A (en) | 1997-10-31 | 1999-08-23 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
US6811996B1 (en) | 1998-10-30 | 2004-11-02 | Daiichi Pharmaceutical Co., Ltd. | DDS compounds and method for assaying the same |
WO2001018080A1 (en) | 1999-09-08 | 2001-03-15 | School Of Pharmacy, University Of London | Uniform molecular weight polymers |
US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
US20070161570A1 (en) * | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003027104A1 (en) * | 2001-09-27 | 2003-04-03 | Idrtech Inc. | Fumagillol derivatives and preparing method thereof |
AU2003215245A1 (en) | 2002-02-15 | 2003-09-09 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
WO2003086382A1 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Tnp-470 polymer conjugates and use thereof |
US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
CN102321584B (zh) | 2003-12-31 | 2014-01-08 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
WO2006084054A2 (en) * | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
WO2009003110A2 (en) | 2007-06-26 | 2008-12-31 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
MX2010005857A (es) | 2007-11-28 | 2010-11-22 | Mersana Therapeutics Inc | Conjugados de analogos de fumagillina biodegradables biocompatibles. |
WO2009141826A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
EP2575887A4 (en) | 2010-05-25 | 2015-01-14 | SynDevRX | CONJUGATES OF OPTIMIZED MEDICINES |
US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
US9320805B2 (en) | 2010-05-25 | 2016-04-26 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
CA2817199C (en) | 2010-11-09 | 2019-01-15 | Zafgen, Inc. | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
BR112013023056A2 (pt) | 2011-03-08 | 2018-10-09 | Zafgen Inc | derivados de oxaespiro [2,5] octano e análogos |
CA2908993C (en) | 2013-04-10 | 2023-05-23 | Syndevrx, Inc. | Metap2 inhibitors and methods of treating obesity |
WO2016103192A1 (en) * | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
DK3386956T3 (da) | 2015-12-10 | 2021-10-11 | Syndevrx Inc | Fumagillolderivater og polymorfer deraf |
EP3402529A1 (en) | 2016-01-11 | 2018-11-21 | Syndevrx, Inc. | Treatment for tumors driven by metabolic dysfunction |
-
2011
- 2011-05-25 US US13/696,743 patent/US9320805B2/en active Active
- 2011-05-25 ES ES11787302T patent/ES2853204T3/es active Active
- 2011-05-25 CN CN201180035859.0A patent/CN103140512B/zh active Active
- 2011-05-25 DK DK11787302.6T patent/DK2576638T3/da active
- 2011-05-25 CN CN201710165886.9A patent/CN107141410B/zh active Active
- 2011-05-25 CN CN201710165498.0A patent/CN107158398B/zh active Active
- 2011-05-25 EP EP11787302.6A patent/EP2576638B1/en active Active
- 2011-05-25 CA CA2828605A patent/CA2828605C/en active Active
- 2011-05-25 WO PCT/US2011/037857 patent/WO2011150022A2/en active Application Filing
- 2011-05-25 EP EP20215305.2A patent/EP3858385A3/en active Pending
-
2016
- 2016-03-09 US US15/065,513 patent/US9730955B2/en active Active
- 2016-03-09 US US15/065,412 patent/US9585909B2/en active Active
-
2017
- 2017-07-26 US US15/660,343 patent/US10159692B2/en active Active
-
2018
- 2018-11-16 US US16/193,253 patent/US10722532B2/en active Active
-
2020
- 2020-06-17 US US16/903,910 patent/US20210128607A1/en not_active Abandoned
-
2022
- 2022-11-08 US US17/983,125 patent/US20230165892A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3858385A3 (en) | 2021-10-27 |
US9320805B2 (en) | 2016-04-26 |
US20210128607A1 (en) | 2021-05-06 |
WO2011150022A3 (en) | 2012-04-12 |
US9585909B2 (en) | 2017-03-07 |
EP2576638A2 (en) | 2013-04-10 |
CN107141410A (zh) | 2017-09-08 |
US20190151353A1 (en) | 2019-05-23 |
US10159692B2 (en) | 2018-12-25 |
US20160256483A1 (en) | 2016-09-08 |
US20130216494A1 (en) | 2013-08-22 |
CN103140512A (zh) | 2013-06-05 |
CN107158398B (zh) | 2022-02-18 |
US9730955B2 (en) | 2017-08-15 |
CN107141410B (zh) | 2022-12-09 |
CN107158398A (zh) | 2017-09-15 |
WO2011150022A2 (en) | 2011-12-01 |
US10722532B2 (en) | 2020-07-28 |
US20160184345A1 (en) | 2016-06-30 |
US20180008630A1 (en) | 2018-01-11 |
CA2828605A1 (en) | 2011-12-01 |
US20230165892A1 (en) | 2023-06-01 |
EP2576638B1 (en) | 2020-12-23 |
EP3858385A2 (en) | 2021-08-04 |
ES2853204T3 (es) | 2021-09-15 |
CN103140512B (zh) | 2017-03-01 |
CA2828605C (en) | 2019-01-15 |
EP2576638A4 (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2576638T3 (da) | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf | |
DK2428450T3 (da) | Doseringsmetode og doseringsindretning | |
DK2624567T3 (da) | Blokinddelingsfremgangsmåde og afkodningsindretning | |
BR112012033478A2 (pt) | dispositivo médico | |
BR112012026334A2 (pt) | aparelho de cateter e introdutor de cateter | |
DK3766408T3 (da) | Indføringsindretninger til medicinsk indretning | |
DK3460056T3 (da) | Terapeutiske nukleasesammensætninger og fremgangsmåder | |
DK2579877T3 (da) | Morpholinopyrimidiner og deres anvendelse til terapi | |
DK2470295T3 (da) | Partikelpumpefremgangsmåder og indretninger | |
DK2619576T3 (da) | Midler og fremgangsmåder til forudsigelse af behandlingsrespons hos en cancerpatient | |
DK3127540T3 (da) | Visse amino-pyrimidiner, sammensætninger deraf, og fremgangsmåder til deres anvendelse | |
BR112013012078A2 (pt) | inibidores de nampt e rock | |
BRPI1013655A8 (pt) | dispositivo e método cirúrgico | |
SMT201700001B (it) | Dispositivo chirurgico oftalmico | |
DK2621481T3 (da) | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser | |
DK3650125T3 (da) | Væskeforstøver og fremgangsmåder | |
DK2544679T3 (da) | Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder | |
DK2584921T3 (da) | Sondeernæringspakninger og fremgangsmåder til anvendelse deraf | |
DK2600715T3 (da) | Flydende ST-246-formuleringer og fremgangsmåder | |
DK2437830T3 (da) | Anordning til lægemiddelleveringsindretning og lægemiddelleveringsindretning | |
ITTO20110641A1 (it) | Composizioni farmaceutiche e metodi di trattamento | |
BR112012007861A2 (pt) | dispositivos médicos e suas bombas | |
DK2975610T3 (da) | Audiokodningsindretning og fremgangsmåde | |
DK2635338T3 (da) | Urologisk anordning | |
DK2353927T3 (da) | Forankrings-system og indretninger |